PL398908A1 - Genetically modified recombinant fibroblast growth factor (FGF1) conjugated to metal or metal oxide nanoparticles, its DNA and amino acid sequence, and use - Google Patents

Genetically modified recombinant fibroblast growth factor (FGF1) conjugated to metal or metal oxide nanoparticles, its DNA and amino acid sequence, and use

Info

Publication number
PL398908A1
PL398908A1 PL398908A PL39890812A PL398908A1 PL 398908 A1 PL398908 A1 PL 398908A1 PL 398908 A PL398908 A PL 398908A PL 39890812 A PL39890812 A PL 39890812A PL 398908 A1 PL398908 A1 PL 398908A1
Authority
PL
Poland
Prior art keywords
metal
metal oxide
fgf1
amino acid
acid sequence
Prior art date
Application number
PL398908A
Other languages
Polish (pl)
Other versions
PL221356B1 (en
Inventor
Anna Szlachcic
Katarzyna Pala
Piotr Jakimowicz
Małgorzata Zakrzewska
Jacek Otlewski
Original Assignee
Wroclawskie Centrum Badan Eit + Spólka Z Ograniczona Odpowiedzialnoscia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wroclawskie Centrum Badan Eit + Spólka Z Ograniczona Odpowiedzialnoscia filed Critical Wroclawskie Centrum Badan Eit + Spólka Z Ograniczona Odpowiedzialnoscia
Priority to PL398908A priority Critical patent/PL221356B1/en
Priority to PCT/PL2013/050010 priority patent/WO2013157973A1/en
Publication of PL398908A1 publication Critical patent/PL398908A1/en
Publication of PL221356B1 publication Critical patent/PL221356B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Przedmiotem wynalazku jest zmodyfikowany genetycznie rekombinowany czynnik wzrostu fibroblastów 1 (FGF1) charakteryzujacy sie tym, ze zawiera mutacje Cys do Ser w pozycji nr 117 w sekwencji aminokwasowej, i który ma mniejsze wlasciwosci agregujace w koniugacie z nanoczastka metalu lub tlenku metalu, korzystnie z nanoczastka zlota. Wynalazek obejmuje równiez koniugat nanoczastki metalu lub tlenku metalu (preferencyjnie nanoczastki zlota) i wspomnianego polipeptydu, a takze jego zastosowanie w wywolywaniu hipertermii spowodowanej ekspozycja koniugatu na swiatlo z zakresu bliskiej podczerwieni (NIR).The subject of the invention is a genetically modified recombinant fibroblast growth factor 1 (FGF1) characterized in that it contains Cys to Ser mutations at position No. 117 in the amino acid sequence, and which has smaller aggregating properties in a conjugate of a metal nanoparticle or metal oxide, preferably a gold nanoparticle . The invention also includes a conjugate of metal or metal oxide nanoparticles (preferably gold nanoparticles) and said polypeptide, as well as its use in the development of hyperthermia caused by exposure of the conjugate to near infrared light (NIR).

PL398908A 2012-04-21 2012-04-21 Genetically modified, recombinant fibroblast growth factor (FGF1) conjugated with nanoparticles of metal or metal oxide, its DNA and amino acid sequence and the use thereof PL221356B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL398908A PL221356B1 (en) 2012-04-21 2012-04-21 Genetically modified, recombinant fibroblast growth factor (FGF1) conjugated with nanoparticles of metal or metal oxide, its DNA and amino acid sequence and the use thereof
PCT/PL2013/050010 WO2013157973A1 (en) 2012-04-21 2013-04-19 Genetically modified recombinant fibroblast growth factor (fgf1) conjugated with metal or metal oxide nanoparticles, its dna and amino acid sequences and use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL398908A PL221356B1 (en) 2012-04-21 2012-04-21 Genetically modified, recombinant fibroblast growth factor (FGF1) conjugated with nanoparticles of metal or metal oxide, its DNA and amino acid sequence and the use thereof

Publications (2)

Publication Number Publication Date
PL398908A1 true PL398908A1 (en) 2013-10-28
PL221356B1 PL221356B1 (en) 2016-03-31

Family

ID=49383795

Family Applications (1)

Application Number Title Priority Date Filing Date
PL398908A PL221356B1 (en) 2012-04-21 2012-04-21 Genetically modified, recombinant fibroblast growth factor (FGF1) conjugated with nanoparticles of metal or metal oxide, its DNA and amino acid sequence and the use thereof

Country Status (2)

Country Link
PL (1) PL221356B1 (en)
WO (1) WO2013157973A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220249611A1 (en) * 2018-10-09 2022-08-11 The Board Of Trustees Of The Leland Stanford Junior University Engineered fibroblast growth factor variants as receptor antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226543A (en) * 1987-10-22 1992-02-25 Merck & Co Inc Recombinant mutant acidic fibroblast growth factor

Also Published As

Publication number Publication date
WO2013157973A1 (en) 2013-10-24
PL221356B1 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
CY1126056T1 (en) NEW AMINOPYRIMIDINE DERIVATIVES
MY183712A (en) Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
GT201400055A (en) FUSION PROTEINS TO TREAT METABOLIC DISORDERS
CY1118714T1 (en) HIGH CONCENTRATION HUMAN CATALOGS IN THE PROTECTION-PROTECTED HUMAN RECEPTORS-2
BR112014029966A2 (en) fibroblast growth factor proteins 21
CY1117695T1 (en) HIGH CONCENTRATION HUMAN VASCULAR ANTIBODIES-2
UA116665C2 (en) Growth differentiation factor 15 (gdf-15) constructs
UY33739A (en) METHODS OF TREATMENT OF DISORDERS ASSOCIATED WITH FGF21
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
MX2021015825A (en) Stable, aqueous antibody formulations.
BR112015032338A2 (en) personal care compositions and articles
FR3009645B1 (en) TRANSPARENT METAL OXIDE NANOPARTICLE COMPOSITIONS, METHODS OF MAKING THE SAME, AND ARTICLES COMPRISING THE SAME
WO2015156870A3 (en) Biopolymer-mediated assembly of nanoparticles using genetically encoded proteins
CL2018001343A1 (en) Lactoferrin for use in the diagnosis or prognosis of Alzheimer's disease or in the diagnosis of parkinson's disease
BR112015032200A2 (en) antibody-drug conjugate with improved stability, method of preparation, pharmaceutical composition and use thereof
NZ598518A (en) Concentrated polypeptide formulations with reduced viscosity
MX2019010852A (en) Lipid-based nanoparticles with enhanced stability.
MX2016003238A (en) Cationic antiseptic compositions.
WO2017123886A8 (en) Methionine sulfoxide reductases for facilitation of recombinant protein folding in vivo or/and for stabilization in vitro
PL398908A1 (en) Genetically modified recombinant fibroblast growth factor (FGF1) conjugated to metal or metal oxide nanoparticles, its DNA and amino acid sequence, and use
MX2016005973A (en) Glycoprotein hormone long-acting superagonists.
BR112015001885A2 (en) super long-acting glycoprotein hormone agonists
MX2015014091A (en) Topical aqueous ophthalmic compositions containing a 1h-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease.
NZ707168A (en) Pharmaceutical composition of insulins
ATE550351T1 (en) VEGF-D MUTANTS AND THEIR USE